Loading
A phase 3 trial of Aminolevulinic acid and Methyl aminolevulinate in Basal cell carcinoma, run by Biofrontera Bioscience GmbH, completed.
Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy is a phase 3 interventional study registered as NCT02144077 by Biofrontera Bioscience GmbH, with 281 participants recorded, started 2014-01-28 and reaching its primary completion in 2015-11-17. Interventions recorded: BF-200 ALA, methyl-aminolevulinate. Conditions recorded: Basal Cell Carcinoma (BCC).
Linked to the drug Methyl aminolevulinate because the registry names it among its interventions and Basal cell carcinoma among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
281 enrolled.
95% CI 87.0 to 96.9; Figures from the ClinicalTrials.gov results section (first posted 2019-03-11), not from a publication · 95% CI 84.6 to 96.0
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall Patient Complete Response Rate Assessed 12 Weeks After the Last PDTprimary | BF-200 ALA | 121 | 93.4% | - | <0.0001 | link |
| Methyl-aminolevulinate | 110 | 91.8% |
Shares Aminolevulinic acid (topical, for photodynamic therapy) and the tag pipeline.
Shares Aminolevulinic acid (topical, for photodynamic therapy) and the tag pipeline.
Shares Basal cell carcinoma and the tag pipeline.
Shares Basal cell carcinoma and the tag pipeline.
Shares Basal cell carcinoma and the tag pipeline.
Shares Basal cell carcinoma and the tag pipeline.
Shares Basal cell carcinoma and the tag pipeline.
Shares Basal cell carcinoma and the tag pipeline.